ホーム › 非小細胞肺癌 › インディアナ州 › Fort Wayne
Fort Wayne、INにおける非小細胞肺癌の臨床試験
Fort Wayneとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する17件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
被験者募集中第2/3相
- Parkview Research Center /ID# 277651, Fort Wayne
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
被験者募集中第1/2相
- Parkview Comprehensive Cancer Center /ID# 271879, Fort Wayne
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
被験者募集中第3相
- Parkview Regional Medical Center, Fort Wayne
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Parkview Research Center at Parkview Regional Medical Center ( Site 0089), Fort Wayne
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
被験者募集中第3相
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Fort Wayne
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- Parkview Research Center at Parkview Regional Medical Center, Fort Wayne
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
被験者募集中第3相
- Research Site, Fort Wayne
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
被験者募集中第1相
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
被験者募集中第1相
- Fort Wayne Medical Oncology and Hematology, Inc, Fort Wayne
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
被験者募集中第3相
- Parkview Packnett Family Cancer Institute, Fort Wayne
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
被験者募集中第1相
- Fort Wayne Medical Oncology and Hematology, Inc /ID# 232593, Fort Wayne
BostonGene and Exigent Genomic INsight Study
被験者募集中観察研究
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY121件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH57件の研究
- Washington, DC55件の研究
Fort Wayneにおける他の研究
- 卵巣がん8件の研究
- がん（全種類）7件の研究
- 慢性リンパ性白血病7件の研究
- 乳がん7件の研究
- 肺がん6件の研究
- 転移性癌6件の研究
- 子宮内膜がん5件の研究
- 悪性黒色腫4件の研究
- 頭頸部扁平上皮癌4件の研究
- トリプルネガティブ乳がん4件の研究
- 大腸癌4件の研究
- 多発性骨髄腫4件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。